How Generative AI and Chat GPT Together with Intelligent Document Review Can Help Pharma Accelerate Filings
Webinar Date/Time: Session 1: Tuesday, April 18th, 2023 at 8am EDT | 1pm BST | 2pm CEST Session 2: Tuesday, April 18th, 2023 at 2pm EDT | 11am PDT | 7pm BST
Self-Driving Clinical Trials are obviously a way off as they are often complicated and unique, much like a trip taken in a ‘self-driving’ car.
However, on the journey to this level of capability there are infrastructure, platform and process improvements that technology can bring today that allow you to build on that philosophy and ensure you are providing the fastest trials and filings that you can.
This webinar will take you on that journey. We will highlight current solutions, what it takes to continue to improve using both structured and unstructured content, and how over time you can build the plug and play tools that cover the time, efficiency and quality metrics you need to work smarter, mitigate risk, and demonstrate Good Clinical Practice (GCP)—all while saving the enterprise valuable time and money.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/hidden-data
Event Overview:
The Inflation Reduction Act has increased pressure on the pharmaceutical industry to speed more products to market—a tall order in an environment where even a single filing critical error can cause months of delays. Pharma has to work smarter, faster and more efficiently and this is where artificial intelligence (AI) can help.
During this session, attendees will learn how to avoid these delays by using AI to tap into the “hidden” information generated in a clinical trial that manual review can’t capture.
As a result, pharma can get to clinical trial close-out faster and regulatory filing with greater speed and precision than ever before, bringing more products to market at a time when they are needed most.
Three key take-aways:
- Why manual review is no longer sufficient or sustainable in today’s environment
- How to stay ahead of the curve by positioning today’s enterprise for tomorrow’s AI solutions
- How to use AI to animate hidden content in various clinical workflows, generating faster filings with higher quality
Speakers:
Gary Shorter
Head, AI and Data Science
IQVIA Technologies
Gary pursues the use of emerging technology to provide new and more efficient capabilities to enhance clinical trial management. This includes development of new design software through to more recent advancements with AI/ML capabilities where his team has developed several micro-products and micro-services that can be plugged in and used by any SaaS solution.
Dimitrios Mizantzidis
Director Product Marketing CDAS
IQVIA Technologies
Dimitrios leads marketing for the Clinical Data Analytics Suite (CDAS) for IQVIA Technologies. He is passionate about solving customer data analytics needs via easy to understand and implement SaaS solutions. Prior to joining IQVIA Technologies in November ‘22, Dimitrios led several marketing teams with other Healthcare IT companies such as GE Healthcare IT and 3M Health Information Systems.
Register Free: https://www.appliedclinicaltrialsonline.com/act_w/hidden-data
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
2 Commerce Drive
Cranbury, NJ 08512
All rights reserved.